止血迅速検査&ポイントオブケア(POC):医療機器パイプライン分析2019

◆英語タイトル:Hemostasis Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019
◆商品コード:GDATA9120292
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥265,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥530,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD7,500 ⇒換算¥795,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Hemostasis Rapid Tests & Point of Care (POC) – Medical Devices Pipeline Assessment, 2019
Summary

GlobalData’s Medical Devices sector report, “Hemostasis Rapid Tests & Point of Care (POC) – Medical Devices Pipeline Assessment, 2019″ provides an overview of Hemostasis Rapid Tests & Point of Care (POC) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hemostasis Rapid Tests & Point of Care (POC) pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Hemostasis Rapid Tests & Point of Care (POC) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Hemostasis Rapid Tests & Point of Care (POC) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Hemostasis Rapid Tests & Point of Care (POC) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

Table of Contents
1.1 List of Tables 3
1.2 List of Figures 4
2 Introduction 5
2.1 Hemostasis Rapid Tests & Point of Care (POC) Overview 5
3 Products under Development 6
3.1 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Stage of Development 6
3.2 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Territory 7
3.3 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Regulatory Path 8
3.4 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Estimated Approval Date 9
4 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products under Development by Companies 10
4.1 Hemostasis Rapid Tests & Point of Care (POC) Companies – Pipeline Products by Stage of Development 10
4.2 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Stage of Development 11
5 Hemostasis Rapid Tests & Point of Care (POC) Companies and Product Overview 12
5.1 Atomo Diagnostics Pty Ltd Company Overview 12
5.1.1 Atomo Diagnostics Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 12
5.2 Carclo Diagnostic Solutions Ltd Company Overview 13
5.2.1 Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview 13
5.3 Cascade Metrix LLC Company Overview 14
5.3.1 Cascade Metrix LLC Pipeline Products & Ongoing Clinical Trials Overview 14
5.4 Edan Instruments Inc Company Overview 15
5.4.1 Edan Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview 15
5.5 EKF Diagnostics Holdings Plc Company Overview 16
5.5.1 EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 16
5.6 Emosis SAS Company Overview 17
5.6.1 Emosis SAS Pipeline Products & Ongoing Clinical Trials Overview 17
5.7 Fraunhofer Institute for Cell Therapy and Immunology Company Overview 18
5.7.1 Fraunhofer Institute for Cell Therapy and Immunology Pipeline Products & Ongoing Clinical Trials Overview 18
5.8 Helena Laboratories Corp Company Overview 19
5.8.1 Helena Laboratories Corp Pipeline Products & Ongoing Clinical Trials Overview 19
5.9 Universal Biosensors Inc Company Overview 26
5.9.1 Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview 26
6 Hemostasis Rapid Tests & Point of Care (POC) – Recent Developments 27
6.1 Apr 08, 2019: Aggredyne receives FDA clearance for ADP platelet aggregation testing cartridge 27
6.2 Nov 22, 2018: EMOSIS reinforces its Intellectual Property and scientific expertise 27
7 Appendix 28
7.1 Methodology 28
7.2 About GlobalData 31
7.3 Contact Us 31
7.4 Disclaimer 31

List of Tables
Table 1: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Stage of Development 6
Table 2: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Territory 7
Table 3: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Regulatory Path 8
Table 4: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Estimated Approval Date 9
Table 5: Hemostasis Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development 10
Table 6: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Stage of Development 11
Table 7: Atomo Diagnostics Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 12
Table 10: Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview 13
Table 13: Cascade Metrix LLC Pipeline Products & Ongoing Clinical Trials Overview 14
Table 16: Edan Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview 15
Table 19: EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 16
Table 22: Emosis SAS Pipeline Products & Ongoing Clinical Trials Overview 17
Table 25: Fraunhofer Institute for Cell Therapy and Immunology Pipeline Products & Ongoing Clinical Trials Overview 18
Table 28: Helena Laboratories Corp Pipeline Products & Ongoing Clinical Trials Overview 19
Table 47: Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview 26
Table 50: Glossary 30

List of Figures
Figure 1: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Stage of Development 6
Figure 2: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Territory 7
Figure 3: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Regulatory Path 8
Figure 4: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Estimated Approval Date 9

【掲載企業】

Atomo Diagnostics Pty Ltd
Carclo Diagnostic Solutions Ltd
Cascade Metrix LLC
Edan Instruments Inc
EKF Diagnostics Holdings Plc
Emosis SAS
Fraunhofer Institute for Cell Therapy and Immunology
Helena Laboratories Corp
Universal Biosensors Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[止血迅速検査&ポイントオブケア(POC):医療機器パイプライン分析2019]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆